Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2003

View Archived Issues

Two cases of OCD behavior described in children after receiving risperidone

Beneficial effects reported for FR-167653 in experimental autoimmune myocarditis

Local methotrexate reported to inhibit tumor progression in mice

High remission rates obtained with sertraline in OCD

Good toxicity profile reported for squalamine in patients with solid tumors

FDA accepts resubmission of Emsam NDA

Selective agonists of thyroid hormone receptors may have utility in obesity

Phase I/II trials cleared for topical PTH (7-34) in chemotherapy-induced alopecia

German permits for 1D09C3 pave way for E.U. clinical trials

AD-237 enters phase IIa study for COPD

New joint venture to develop bioresorbable drug-eluting cardiovascular stent

Novel HCV NS5B inhibitors prepared and tested at GSK

Novel MCH receptor modulators under study at Neurogen

Bayer team presents new Rho kinase inhibitors in recent patent

New IMPDH inhibitors and their use in psoriasis, arthritis and transplant rejection

New LXR modulators in Pharmacia development pipeline

Cytochroma discovers new retinoic acid metabolizing cytochrome P450

Canadian approval for initiation of Actipore trial

Effect of DN-101 on chemotherapy for NSCLC evaluated in new phase I/II trial

Approvable letter for Zometa for patients with bone metastases from advanced cancer

Approval for pediatric extension of Fludara

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...